Eczema does not transform into cancer the way a benign mole can become melanoma. The two are fundamentally different processes, and having atopic dermatitis (the most common form of eczema) does not mean your skin is on some slow march toward malignancy. That said, the relationship between eczema and cancer is not a clean zero. Large population studies show small but real statistical links between eczema and certain cancers, particularly lymphoma, while a rare skin cancer can masquerade as stubborn eczema for months or years. Understanding where the genuine risks lie, and where the fears are overblown, requires sorting through several separate questions that often get tangled together.
Why the Question Comes Up in the First Place
Part of the reason people worry about eczema and cancer is that eczema involves chronic inflammation, and chronic inflammation is a known driver of cancer in other contexts. Chronic hepatitis raises liver cancer risk, long-standing ulcerative colitis raises colon cancer risk, and so the leap to “chronic skin inflammation might cause skin cancer” feels intuitive. The other part is practical: some eczema medications carry black-box warnings about cancer, which understandably alarms anyone reading the label on a prescription cream for their child. And then there is the clinical reality that a specific type of skin lymphoma can look almost indistinguishable from severe eczema, leading to delayed diagnoses that make the two conditions seem more connected than they are.
The Lymphoma Connection
Of all the cancer types studied in relation to eczema, lymphoma shows the most consistent link. A 2025 systematic review and meta-analysis found that people with atopic dermatitis had a modestly elevated risk of both Hodgkin lymphoma and non-Hodgkin lymphoma, with the risk climbing alongside disease severity. People with severe eczema showed the highest effect size, roughly two and a half times the risk compared to the general population.1PubMed Central. Atopic dermatitis and lymphoma risk: a systematic review and meta-analysis An earlier meta-analysis similarly reported a modestly increased lymphoma risk among eczema patients, with severity appearing to be a significant factor.2PubMed. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis
A large population-based cohort study in the United Kingdom helps put these numbers into everyday terms. Among over 400,000 children with eczema, the overall rate of any cancer was virtually the same as in children without eczema. However, children with severe eczema had about three times the risk of developing lymphoma specifically (excluding cutaneous T-cell lymphoma). In adults, the overall cancer rate was again statistically identical between those with and without eczema, but adults with severe disease had roughly double the lymphoma risk.3Oxford Academic (British Journal of Dermatology). Malignancy risk in patients with atopic dermatitis: a population-based cohort study
These elevated risks sound alarming in relative terms, but they are built on top of a cancer that is already quite rare. Lymphoma affects a small fraction of the general population each year, so even doubling or tripling that small baseline still leaves the absolute risk low for any individual person with eczema. The finding matters most as a research signal pointing to shared immune pathways rather than as a practical warning that eczema patients should expect lymphoma.
When a Skin Cancer Mimics Eczema
One of the more unsettling aspects of the eczema-cancer overlap has nothing to do with eczema causing cancer. It involves a rare cancer, cutaneous T-cell lymphoma, that can look and feel remarkably like bad eczema. CTCL, particularly its most common subtype called mycosis fungoides, often starts as flat, scaly, itchy patches on the skin. Early-stage biopsies can be ambiguous, and histological features overlap enough to fool pathologists.
A published case report describes a 61-year-old man with severe, treatment-resistant skin inflammation initially managed as atopic dermatitis. Despite standard therapies, the disease kept progressing. It was only after repeated biopsies and specialized testing that the true diagnosis of cutaneous T-cell lymphoma was confirmed.4Europe PMC. Severe adult-onset atopic dermatitis mistaken for cutaneous T-cell lymphoma in a medically complex patient This is not an isolated quirk. The clinical literature consistently flags the difficulty of distinguishing these two conditions, especially in adults who develop “eczema” for the first time later in life.
Dermatologists have identified several red flags that warrant further investigation. A clinician’s guide to CTCL presenting as eczema-like dermatitis recommends obtaining multiple biopsies when the rash does not respond to standard eczema treatments, when eczema first appears in adulthood with no prior history, when the rash develops unusually large or nodular lesions, or when earlier biopsies showed ambiguous findings. Stopping corticosteroids at least two weeks before a biopsy is recommended, because steroids can mask the histological clues that distinguish lymphoma from eczema.5International Journal of Women’s Dermatology. A clinician’s guide to cutaneous T-cell lymphoma presenting as recalcitrant eczematous dermatitis in adults
The practical takeaway is straightforward: eczema that starts in midlife and refuses to improve with usual treatments deserves a closer look. This is not eczema transforming into cancer. It is cancer being misidentified as eczema.
Eczema and Skin Cancer Risk
Beyond lymphoma, researchers have also looked at whether eczema affects your odds of developing common skin cancers like basal cell carcinoma and squamous cell carcinoma. A systematic review pooling observational data found a statistically significant association between atopic dermatitis and both types. The increase for basal cell carcinoma was roughly 50 percent, and for squamous cell carcinoma it was nearly double.6PubMed Central. Atopic Dermatitis and Skin Cancer Risk: A Systematic Review
But here the story gets complicated. The same UK cohort study mentioned earlier found that eczema was associated with a slightly higher skin cancer risk overall, but also with a slightly lower risk of solid organ cancers in adults.3Oxford Academic (British Journal of Dermatology). Malignancy risk in patients with atopic dermatitis: a population-based cohort study And a case-control study examining allergy history and skin cancer found an inverse association between allergic conditions and early-onset basal cell carcinoma, at least in women.7PubMed Central. History of allergy and atopic dermatitis in relation to squamous cell and Basal cell carcinoma of the skin The evidence, in other words, does not point cleanly in one direction. Confounding factors make this particularly hard to untangle: people with eczema see dermatologists more often (increasing the chance of any skin lesion being caught and biopsied), and some eczema treatments involve UV light exposure, which is a known skin cancer risk factor on its own.
Could Eczema Actually Protect Against Some Cancers?
One of the more counterintuitive findings in this field is that allergic conditions, including eczema, may be associated with a lower risk of certain cancers. The idea has a rough biological logic: the overactive immune surveillance that causes the misery of eczema might also be better at spotting and eliminating abnormal cells before they become tumors. A case-control study of men in Montreal noted that allergic conditions resulting from a hyperreactive immune system might lead to more efficient elimination of abnormal cells.8PubMed. History of asthma or eczema and cancer risk among men: a population-based case-control study in Montreal, Quebec, Canada
A review examining cancer incidence among people with multiple allergic conditions found that those who had eczema, asthma, and allergic rhinitis together had a meaningfully reduced rate of overall cancer, about 40 percent lower than expected.9PubMed. Eczema and cancer risk: a critical appraisal and review of the literature Animal research has offered a possible mechanism: mice with disrupted skin barrier proteins (similar to the barrier defect seen in eczema) developed far fewer chemically induced skin tumors, roughly sixfold fewer, compared to normal mice.10eLife. Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility
The immune biology is more nuanced than a simple “overactive immune system kills cancer.” The type of immune response dominant in eczema, driven by a specific arm of the immune system, has traditionally been viewed as promoting tumor growth by encouraging blood vessel formation and dampening the immune cells that kill tumors. But a growing body of evidence shows this same arm of immunity can also collaborate with other immune cells to mount anti-tumor responses.11Humana Press. The role of Th2-mediated anti-tumor immunity in tumor surveillance and clearance The net effect likely depends on the specific cancer type, where it is in the body, and the individual’s particular immune profile. It is far too early to call eczema protective against cancer in any clinically useful way, but the data are interesting enough to push back against the assumption that chronic skin inflammation straightforwardly raises cancer risk.
Do Eczema Treatments Cause Cancer?
For many patients and parents, the cancer question is really a treatment question. The prescription creams, light therapy, and newer injectable medications used for eczema all come with safety discussions that sometimes include the word “cancer.” Here is what the evidence actually says across the major treatment categories.
Topical Calcineurin Inhibitors
Pimecrolimus and tacrolimus creams have carried FDA black-box warnings about a theoretical risk of cancer, including lymphoma, since 2006. Those warnings were based on the cancer-causing potential observed in organ transplant patients taking high systemic doses of similar drugs, not on evidence from the skin creams themselves. Since then, the data have been reassuring. A systematic review and meta-analysis published in The Lancet Child & Adolescent Health found that the absolute risk of any cancer with topical calcineurin inhibitor exposure was essentially the same as in controls, about 4.7 per 1,000 versus 4.6 per 1,000.12PubMed. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis A long-term safety study specifically tracking children treated with topical tacrolimus found a cancer incidence rate matching the general population exactly, with zero lymphomas observed over more than 44,000 person-years of follow-up.13PubMed. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis
One meta-analysis did find a statistically elevated lymphoma signal with calcineurin inhibitor use, but the researchers noted that this likely reflects the underlying severity of eczema in users rather than the medication itself, since severe eczema independently raises lymphoma risk as described above.14JAMA Dermatology. Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis This is a textbook example of confounding by indication: the people using stronger treatments are the people with worse disease, and worse disease is what carries the risk.
Topical Corticosteroids
Steroid creams are the backbone of eczema treatment, and patients sometimes wonder whether long-term use could cause skin cancer. A systematic review looking specifically at this question found that no studies existed to establish or refute any link between long-term topical corticosteroid use and skin cancer.15PubMed. Long-term topical corticosteroid use and risk of skin cancer: a systematic review The absence of evidence is not proof of safety, but given the many decades of widespread corticosteroid use, the fact that no signal has emerged is itself somewhat reassuring.
Dupilumab and Other Biologics
Dupilumab, the injectable biologic that blocks key immune signals driving eczema, has been available since 2017. Because it suppresses part of the immune system, cancer risk has been a concern from the start. A retrospective analysis of patients followed for at least six years found no increased risk of malignancy with dupilumab treatment. In fact, patients exposed to the drug had statistically lower rates of internal malignancy and common skin cancers compared to unexposed patients.16JAAD Reviews. Dupilumab in cancer patients: A narrative review of cutaneous toxicities, safety considerations, and emerging oncologic insights A case series of patients who already had cancer and were treated with dupilumab for concurrent eczema showed no cancer progressions or relapses during treatment.17PubMed Central. Real-Life Safety and Effectiveness of Dupilumab in Patients with Concomitant Malignancies: a Case Series These findings are still accumulating, and larger long-term studies will eventually paint a more complete picture, but the early evidence does not suggest dupilumab raises cancer risk.
JAK Inhibitors
Oral JAK inhibitors represent the newest class of systemic eczema treatments and come with the most active safety debate. These drugs suppress broader immune signaling pathways than dupilumab, raising theoretical concerns about infections and malignancy. In dermatology trials, rates of skin cancer and other cancers in patients on JAK inhibitors were generally low and close to placebo rates, and most patients who developed these events had preexisting risk factors.18PubMed Central. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring However, a meta-analysis spanning multiple disease indications found that compared to another class of immune-suppressing medications, JAK inhibitors were associated with about a 50 percent higher malignancy incidence.19Annals of the Rheumatic Diseases. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications The signal is driven largely by data from rheumatology patients, who tend to be older and have more cancer risk factors than the average eczema patient. Still, this is the one treatment category where ongoing caution is genuinely warranted, and many prescribers reserve oral JAK inhibitors for patients who have not responded to other options.
Phototherapy and Skin Cancer
UV-B light therapy is a well-established treatment for moderate-to-severe eczema, and since UV radiation is a known cause of skin cancer, the question of long-term risk is reasonable. The evidence here presents an interesting split. A multi-center registry study of nearly 5,000 patients who received narrowband UV-B found elevated rates of basal cell carcinoma, squamous cell carcinoma, and melanoma compared to what would be expected in the general population.20PubMed Central. Skin Cancer Risk of Narrow-Band UV-B (TL-01) Phototherapy: A Multi-Center Registry Study with 4,815 Patients However, a population-based study looking specifically at eczema patients found no increase in skin cancer risk among those treated with UV-B phototherapy compared to eczema patients who did not receive it.21PubMed. Ultraviolet B phototherapy does not increase the risk of skin cancer among patients with atopic dermatitis: A population-based retrospective cohort study
The discrepancy likely reflects the fact that the registry study included patients with various skin conditions (not just eczema) and may capture selection effects: people needing phototherapy may have inherently different skin types or UV exposure histories. The eczema-specific data are more reassuring, but this remains an area where the number of treatment sessions and cumulative UV dose probably matter. Discussing a reasonable stopping point or maintenance schedule with your dermatologist is sensible if you are on long-term phototherapy.
Skin Bacteria and a Speculative Link
Eczema-affected skin is heavily colonized by Staphylococcus aureus, a bacterium that thrives in the disrupted skin barrier. Some researchers have explored whether this chronic bacterial presence could contribute to cancer risk, since S. aureus produces toxins and metabolites that can interact with host cells in ways that might theoretically encourage cancerous changes.22PubMed. Microbial mysteries: Staphylococcus aureus and the enigma of carcinogenesis This is genuinely speculative at this stage. The research describes plausible biological mechanisms in laboratory settings, not demonstrated cancer risk in people with eczema. It is worth mentioning because it represents an active research frontier, but it should not add to anyone’s anxiety about their eczema.
Biological Aging in Eczema Skin
A recent systematic review found that children with atopic dermatitis showed accelerated biological aging in their skin cells as measured by several epigenetic aging clocks.23PubMed. Systematic Review of Accelerated Epigenetic Aging in Chronic Inflammatory Dermatology Conditions Epigenetic aging refers to chemical changes in DNA that accumulate with age and inflammation, and faster biological aging has been loosely associated with higher cancer risk in other contexts. Whether this accelerated aging translates into any meaningful cancer risk for people with eczema is unknown. The finding is mostly interesting for what it reveals about the systemic toll of chronic inflammation on skin biology. It may eventually help explain why severe, long-standing eczema shows different cancer associations than mild disease, but it is not something you need to act on today.
When Eczema Patients Should Actually Worry
For the vast majority of people with eczema, cancer risk is not meaningfully different from the general population. The overall cancer incidence among both children and adults with eczema tracks closely with population norms, as the UK cohort data showed. The situations where genuine vigilance makes sense are specific:
- New-onset eczema in adulthood: if you develop widespread, itchy, scaly skin disease for the first time in your forties, fifties, or beyond, and it does not respond to standard treatments, your dermatologist should consider cutaneous T-cell lymphoma in the workup.
- Severe, treatment-resistant disease: eczema that has been getting progressively worse despite appropriate therapy warrants repeat biopsies, especially if patches are evolving in size, shape, or texture.
- Long-term immunosuppression: if you are on systemic immunosuppressive drugs, particularly older agents like cyclosporine or mycophenolate, the immunosuppression itself can raise cancer risk. This is a drug effect, not an eczema effect, and your doctor should be monitoring accordingly.
Anxiety about cancer is common among eczema patients, and research has shown that psychological factors like anxiety and depression significantly influence eczema-related quality of life and self-management.24Skin Health and Disease / Wiley Online Library. The influence of self-management, anxiety and depression on chronic eczema-related quality of life Worrying about cancer on top of managing a chronic, visible, uncomfortable skin condition adds a burden that, for most patients, is disproportionate to the actual risk. If the fear of cancer is making you avoid effective treatments, that avoidance is likely doing more harm than any theoretical cancer risk from the treatment itself.